Higado Graso: Ultrasonido Y Correlacion Anatomopatologica

G, Paula Csendes; G, Paola Paolinelli; M, David Busel; A, Verónica Venturelli; Rodríguez, Jorge

doi:10.4067/s0717-93082004000200003

Cited by 7 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ultrasound-determined subcutaneous fat was defined as the distance between the skin and the external face of the rectus abdominal muscle, and visceral fat as the distance between the internal face of the same muscle and the anterior wall of the aorta (Ribeiro-Filho et al, 2003). NAFLD diagnosis was made in subjects with absent-to-low alcohol consumption (b 30 g/day) using the following criteria: a) increase in liver echogenicity with respect to the kidney, b) low or absent visualization of the portal vessels, and c) presence of hepatomegaly (Csendes et al, 2004). A fasting blood sample was taken to determine glycemia, lipid profile, insulin, C-reactive protein and uric acid.…”

Section: Methodsmentioning

confidence: 99%

Nonalcoholic fatty liver disease is associated with insulin resistance in a young Hispanic population

Pérez

Gonzáles

Olarte

et al. 2011

Preventive Medicine

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Nonalcoholic fatty liver disease is associated with insulin resistance in a young Hispanic population

Pérez

Gonzáles

Olarte

et al. 2011

Preventive Medicine

View full text Add to dashboard Cite

“…Enrolled patients were eligible for randomization if liver fat infiltration was confirmed by ultrasonography [26]. …”

Section: Methodsmentioning

confidence: 99%

Effects of D-002, a mixture of high molecular weight beeswax alcohols, on patients with nonalcoholic fatty liver disease

Illnait

Rodríguez

Mendoza

et al. 2013

Korean J Intern Med

View full text Add to dashboard Cite

Background/AimsNonalcoholic fatty liver disease (NAFLD) is intimately related to insulin resistance and ranges from a benign course to liver fibrosis and cirrhosis. NAFLD management mainly involves dietary modification and weight loss. Although no fully successful pharmacological intervention is available, alternative therapies to treat NAFLD have shown promising results. Experimental studies have shown that D-002, a mixture of beeswax alcohols with antioxidant effects, is hepatoprotective. The aim of this study was to investigate the efficacy and safety of D-002 in patients with NALFD.MethodsFifty patients with NAFLD were randomized to receive a placebo or D-002 (100 mg/day) for 24 weeks. The primary endpoint was a significant ultrasonography-detected reduction of liver fat infiltration versus a placebo. Secondary endpoints were decreases in the homeostatic model assessment (HOMA) index, insulin levels, serum liver enzymes, increases in plasma total antioxidant status (TAS) and improved clinical symptoms versus the placebo recipients.ResultsAt randomization, all indicators were comparable in both groups. At study completion, seven (28.0%) D-002-patients, but none of the placebo recipients, exhibited a normal liver echo pattern on ultrasonography (p < 0.01). Also, D-002 significantly reduced (p < 0.01 vs. baseline and placebo) the HOMA index and insulin levels and increased the TAS, but did not affect other parameters. The proportion of D-002-patients (12/25, 48.0%) showing symptom improvement was higher (p < 0.001) than that of the placebo group (1/25, 4.0%). The treatment was safe and well tolerated. Three patients in each group withdrew from the study.ConclusionsD-002 (100 mg/day) improved ultrasonographic findings, indicators of insulin resistance, plasma TAS and clinical evolution on NAFLD patients. Further studies, however, are needed to confirm these results.

show abstract

“…A hepatic ultrasound (US) test will also be performed at the beginning of the two intervention periods, as well as at the end of the intervention periods. US diagnostic criteria for diagnosis and grading of hepatic steatosis will be used [ 16 ]. Smoking habits and anxiolytic and antihistaminic drug intake will also be recorded.…”

Section: Method/designmentioning

confidence: 99%

Evaluation of the effect of Lactobacillus reuteri V3401 on biomarkers of inflammation, cardiovascular risk and liver steatosis in obese adults with metabolic syndrome: a randomized clinical trial (PROSIR)

Jiménez

Martínez-Ramírez

Tercero-Lozano

et al. 2018

BMC Complement Altern Med

View full text Add to dashboard Cite

BackgroundObesity is characterized by increased fat mass and is associated with the development of insulin resistance syndrome (IRS), usually known as metabolic syndrome. The alteration of the intestinal microbiota composition has a role in the development of IRS associated with obesity, and probiotics, which are live microorganisms that confer a health benefit to the host, contribute to restore intestinal microbiota homeostasis and lower peripheral tissue insulin resistance. We aim to evaluate the effects of the probiotic strain Lactobacillus reuteri (L. reuteri) V3401 on the composition of intestinal microbiota, markers of insulin resistance and biomarkers of inflammation, cardiovascular risk, and hepatic steatosis in patients with overweight and obesity exhibiting IRS.Methods/designWe describe a randomized, double-blind, crossover, placebo-controlled, and single-centre trial. Sixty participants (aged 18 to 65 years) diagnosed with IRS will be randomized in a 1:1 ratio to receive either a daily dose of placebo or 5 × 109 colony-forming units of L. reuteri V3401. The study will consist of two intervention periods of 12 weeks separated by a washout period of 6 weeks and preceded by another washout period of 2 weeks. The primary outcome will be the change in plasma lipopolysaccharide (LPS) levels at 12 weeks. Secondary outcomes will include anthropometric parameters, lipid profile, glucose metabolism, microbiota composition, hepatic steatosis, and inflammatory and cardiovascular biomarkers. Blood and stool samples will be collected at baseline, at the midpoint (only stool samples) and immediately after each intervention period. Luminex technology will be used to measure interleukins. For statistical analysis, a mixed ANOVA model will be employed to calculate changes in the outcome variables.DiscussionThis is the first time that L. reuteri V3401 will be evaluated in patients with IRS. Therefore, this study will provide valuable scientific information about the effects of this strain in metabolic syndrome patients.Trial registrationThe trial has been retrospectively registered in ClinicalTrials.gov on the 23rd November 2016 (ID: NCT02972567), during the recruitment phase.Electronic supplementary materialThe online version of this article (10.1186/s12906-018-2371-x) contains supplementary material, which is available to authorized users.

show abstract

Higado Graso: Ultrasonido Y Correlacion Anatomopatologica

Cited by 7 publications

References 0 publications

Nonalcoholic fatty liver disease is associated with insulin resistance in a young Hispanic population

Nonalcoholic fatty liver disease is associated with insulin resistance in a young Hispanic population

Effects of D-002, a mixture of high molecular weight beeswax alcohols, on patients with nonalcoholic fatty liver disease

Evaluation of the effect of Lactobacillus reuteri V3401 on biomarkers of inflammation, cardiovascular risk and liver steatosis in obese adults with metabolic syndrome: a randomized clinical trial (PROSIR)

Contact Info

Product

Resources

About